データなし
データなし
Press Release: Palvella Therapeutics Announces Closing of Merger With Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
ピエリス・ファーマシューティカルズ | 10-Q:Q3 2024 四半期報告書
Pieris Pharmaceuticals' Merger Target Palvella Doses First Patient in Phase 3 Trial of Lymphatic Drug
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN Rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference